Trial Rescue & Reconnaissance

A Phase III oncology trial faced enrollment challenges — high site decline rates and too few eligible patients passing screening. Citeline conducted assessments to determine whether the sponsor had targeted the wrong sites or whether protocol design created barriers. The analysis validated that the sponsor's original site selection was generally sound while identifying "199 additional high-quality US sites and eight countries for potential expansion." The findings supported a protocol amendment projected to boost enrollment by 15% to 20%.

Norstella is a holding company merging several pharma-intelligence brands — Citeline (trial intelligence), Evaluate (forecasting), MMIT (payer/formulary data) and Panalgo (real-world analytics) — into one data asset.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.